| SOLENO THERAPEUTICS |
| USA |
| Gesundheit |
| US8342033094 / A3DS0P |
| 6XC (Frankfurt) / SLNO (NASDAQ) |
| FRA:6XC, ETR:6XC, 6XC:GR, NASDAQ:SLNO |
| - |
| https://soleno.life/ |
|
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare diseases. Its primary product, VYKAT XR (diazoxide choline exte..
>Volltext.. |
| 1749.52 Mio. EUR |
| 1533.24 Mio. EUR |
| 165.24 Mio. EUR |
| 14.72 Mio. EUR |
| 17.77 Mio. EUR |
| 0.22 EUR |
| 45.61 Mio. EUR |
| 60.84 Mio. EUR |
| 40.56 Mio. EUR |
| 4.98 |
| - |
| - |
| - |
| - |
| - |
| - |
| SOLENO |
| 13.03.26 |